Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries

Formulation development was performed with the live, attenuated, human neonatal rotavirus vaccine candidate (RV3-BB) with three main objectives to facilitate use in low- and middle- income countries including (1) a liquid, 2–8°C stable vaccine, (2) no necessity for pre-neutralization of gastric acid...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Prashant, Shukla, Ravi S., Patel, Ashaben, Pullagurla, Swathi R., Bird, Christopher, Ogun, Oluwadara, Kumru, Ozan S., Hamidi, Ahd, Hoeksema, Femke, Yallop, Christopher, Bines, Julie E., Joshi, Sangeeta B., Volkin, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189091/
https://www.ncbi.nlm.nih.gov/pubmed/33861183
http://dx.doi.org/10.1080/21645515.2021.1885279

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189091/
https://www.ncbi.nlm.nih.gov/pubmed/33861183
http://dx.doi.org/10.1080/21645515.2021.1885279

Ejemplares similares